Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This trial is designed to investigate the safety, dosing schedule, and efficacy of the
combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy
for recurrent prostate cancer. This trial is at its Phase II stage. As of July 23, 2013 Arm B
was closed to accrual, all the remaining slots in accrual will be allocated to Arm A.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health